Company news

INmune Bio Inc. news

Latest news releases, newest first. Pick a year for every news release, call and deck from that year.

View company

INmune Bio, Inc. Announces Two Presentations at the 2021 British Society of Immunology Congress and Provides 119-day data on First patient in MDS trial.

November 30, 2021

INmune Bio, Inc. Announces Third Quarter 2021 Results and Provides Business Update

November 2, 2021

INmune Bio, Inc. Announces Multiple Oral and Poster Presentations at the 14th Clinical Trials on Alzheimer’s Disease (CTAD) Annual Meeting

October 26, 2021

INmune Bio, Inc. to Report Third Quarter 2021 Financial Results and Provide a Corporate Update on Wednesday, November 3

October 24, 2021

INmune Bio, Inc. Announces Participation at Upcoming Investor Conferences

September 19, 2021

Alzheimer’s Patients Treated with INmune Bio’s XPro™ Show Reduction in CSF Phospho-Tau and Evidence of Remyelination

August 31, 2021

INmune Bio, Inc. Announces Biomarker Data Demonstrating that the First Patient Treated with its NK Cell Priming “Pseudokine”, INKmune™, Successfully Produced Memory-Like NK Cells

August 24, 2021

INmune Bio, Inc. Announces Second Quarter 2021 Results and Provides Business Update

August 3, 2021

INmune Bio, Inc. to Report Second Quarter 2021 Financial Results and Provide a Corporate Update on Wednesday, August 4

July 27, 2021

INmune Bio, Inc. Announces Design of Upcoming Phase 2 Alzheimer’s Disease Clinical Trial and New Phase 1b AD Biomarker Data

July 25, 2021

INmune Bio acquires LUMICKS' z-Movi® Cell Avidity Analyzer to accelerate the development of its NK cell platform for cancer treatments

July 21, 2021

INmune Bio, Inc. Announces Poster Presentation and Plenary Talk at the Alzheimer’s Association International Conference 2021

July 18, 2021

INmune Bio, Inc. announces $40 million registered direct offering

July 13, 2021

INmune Bio, Inc. Announces First Patient Treated with NK cell priming “pseudokine” INKmune in High-Risk Myelodysplastic Syndrome (MDS)

July 11, 2021

INmune Bio, Inc. Announces $15 Million Credit Facility to Purchase Xencor Option to Reduce Future Dilution

June 13, 2021

INmune Bio, Inc. Announces Lead Drug Candidate XPro1595 Receives Chemical Drug Name pegipanermin from USAN

June 1, 2021

INmune Bio, Inc. Announces First Quarter 2021 Results and Provides Business Update

May 4, 2021

INmune Bio, Inc. to Report First Quarter 2021 Financial Results and Provide a Corporate Update on Wednesday, May 5

April 27, 2021

INmune Bio, Inc. Announces Participation in Fireside Chat at the B Riley Neurosciences Conference

April 25, 2021

INmune Bio, Inc. Announces Professor Mark Lowdell, PhD, CSO to Deliver Presentations at Two Upcoming Medical Meetings

March 21, 2021

INmune Bio, Inc. Announces Participation at Upcoming Virtual Investor Conferences in March 2021

March 7, 2021

INmune Bio, Inc. Announces Fourth Quarter and Full Year 2020 Results and Provides Business Update

March 3, 2021

INmune Bio, Inc. to Report Fourth Quarter and Full Year 2020 Financial Results and Provide a Corporate Update on Thursday, March 4

February 24, 2021

INmune Bio, Inc. Announces XPro1595 Found to Decrease Neuroinflammation and Neurodegeneration Biomarkers in Patients with Alzheimer’s Disease in Phase 1b Trial

January 20, 2021

INmune Bio, Inc. Announces First Patient Dosed in Phase 2 Trial of Quellor™ for Pulmonary Complications in COVID-19 Patients

November 8, 2020

INmune Bio, Inc. Announces Third Quarter Results and Provides Business Update

November 4, 2020

INmune Bio, Inc. to Report Third Quarter 2020 Financial Results and Provide a Corporate Update on Thursday, November 5

October 28, 2020

INmune Bio, Inc. Presents Preliminary Phase I Data at 21st International Conference on Alzheimer’s Drug Discovery

October 4, 2020

INmune Bio, Inc. Awarded $2.9 Million NIH Small Business Innovation Research Grant to Support Phase 2 Study of XPro1595 in Patients with Treatment Resistant Depression

September 15, 2020

INmune Bio, Inc. Announces Issuance of Patent from U.S. Patent & Trademark Office Covering INKmune™ Therapy

September 2, 2020

INmune Bio, Inc. Announces FDA Acceptance of IND Application to Evaluate Quellor™ in a Blinded Randomized Phase 2 Trial for Immune Mediated Complications in COVID-19 Patients

August 31, 2020

European Patent Granted Covering INmune Bio’s XPro1595

August 12, 2020

INmune Bio, Inc. Announces Second Quarter 2020 Results and Provides Business Update

August 4, 2020

INmune Bio, Inc. Schedules Conference Call to Report 2020 Second Quarter Financial Results

July 30, 2020

INmune Bio, Inc. Announces Closing of $25 Million Public Offering of Common Stock Including Full Exercise of Underwriters’ Over-Allotment Option

July 19, 2020

INmune Bio, Inc. Prices Public Offering of Common Stock

July 15, 2020

INmune Bio, Inc. Announces Proposed Public Offering of Common Stock

July 14, 2020

INmune Bio, Inc. Announces Interim Phase Ib Data Demonstrating That XPro1595 Decreases Neuroinflammation in Patients with Alzheimer’s Disease

July 12, 2020

INmune Bio, Inc. to Announce Interim Data from Phase Ib Clinical Study of XPro1595 in Patients with Alzheimer’s Disease Prior to Start of AAIC 2020

July 8, 2020

INmune Bio, Inc. Receives Regulatory Approval from UK MHRA to Initiate Phase I Trial of INKmune in Patients with High-risk MDS

June 10, 2020

INmune Bio, Inc. Announces First Quarter 2020 Results and Provides Business Update

May 13, 2020

INmune Bio Inc’s INB03 Inhibits Cell Migration, Tumor Growth, and Induces Innate Immune Response in Pre-clinical Models of Trastuzumab-Resistant HER2+ Breast Cancer

May 10, 2020

INmune Bio, Inc. to Host First Quarter 2020 Earnings Conference Call

May 5, 2020

INmune Bio Announces Allowance of U.S. Patent Covering Method for Treating Cancer by In Vivo Priming of Natural Killer Cells

April 21, 2020

INmune Bio, Inc. Announces Initiation of Clinical Program Targeting Soluble TNF to Determine if the Company’s TNF Inhibitor (DN-TNF) Platform May Prevent Complications of Cytokine Storm Caused by COVID-19

April 19, 2020

INmune Bio, Inc. Reports Fourth Quarter and Full Year 2019 Results - Drug Pipeline Expands to Now Include Cancer, Alzheimer’s Disease and NASH

March 10, 2020

INmune Bio, Inc. to Present at the 32nd Annual ROTH Conference on March 17

March 4, 2020

INmune Bio, Inc. Schedules Conference Call to Report 2019 Fourth Quarter and Full Year Financial Results

February 26, 2020

INmune Bio, Inc. Awarded $500,000 Grant for Development of Novel Treatment to Reprogram Innate Immune System in People Living with ALS

February 9, 2020

INmune Bio, Inc. Announces Data on its Lead Compound Which Highlights The Potential to Lower The Risk of Alzheimer's Disease in Obese Individuals

January 1, 2020

← Newer news releases · Older news releases →

Calls

The 5 newest of 22 calls. Every call is listed under its year.

Decks

The 5 newest of 43 decks. Every deck is listed under its year.